- Home
- CRDL vs CNTX Comparison
CRDL vs CNTX Comparison
Compare CRDL & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- CNTX
- Stock Information
- Founded
- CRDL 2017
- CNTX 2015
- Country
- CRDL Canada
- CNTX United States
- Employees
- CRDL N/A
- CNTX N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRDL Health Care
- CNTX Health Care
- Exchange
- CRDL Nasdaq
- CNTX Nasdaq
- Market Cap
- CRDL 142.5M
- CNTX 149.6M
- IPO Year
- CRDL N/A
- CNTX 2021
- Fundamental
- Price
- CRDL $1.58
- CNTX $1.50
- Analyst Decision
- CRDL Strong Buy
- CNTX Strong Buy
- Analyst Count
- CRDL 3
- CNTX 3
- Target Price
- CRDL $9.00
- CNTX $6.83
- AVG Volume (30 Days)
- CRDL 421.9K
- CNTX 210.1K
- Earning Date
- CRDL 11-14-2024
- CNTX 11-06-2024
- Dividend Yield
- CRDL N/A
- CNTX N/A
- EPS Growth
- CRDL N/A
- CNTX N/A
- EPS
- CRDL N/A
- CNTX N/A
- Revenue
- CRDL N/A
- CNTX N/A
- Revenue This Year
- CRDL N/A
- CNTX N/A
- Revenue Next Year
- CRDL N/A
- CNTX N/A
- P/E Ratio
- CRDL N/A
- CNTX N/A
- Revenue Growth
- CRDL N/A
- CNTX N/A
- 52 Week Low
- CRDL $0.79
- CNTX $0.77
- 52 Week High
- CRDL $3.12
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CRDL 30.69
- CNTX 25.94
- Support Level
- CRDL $1.83
- CNTX $1.56
- Resistance Level
- CRDL $1.92
- CNTX $2.32
- Average True Range (ATR)
- CRDL 0.15
- CNTX 0.16
- MACD
- CRDL -0.04
- CNTX -0.07
- Stochastic Oscillator
- CRDL 12.00
- CNTX 17.88
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.